Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)

Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, Sabine Wilson, Iakov I Davydov, Nicolas Staedler, José Duarte, Iris Martinez Quetglas, Eveline Nüesch, Marta Cañamero, Evelyne Chesné, George Au-Yeung, Erika Hamilton, Stephanie Lheureux, Debra L Richardson, Iben Spanggaard, Bruno Gomes, Izolda Franjkovic, Mark DeMario, Martin Kornacker, Katharina Lechner
doi: https://doi.org/10.1101/2024.07.28.24309665

Article Information

doi 
https://doi.org/10.1101/2024.07.28.24309665
History 
  • July 29, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Daniel Marbach1,*,†,
  2. Jurriaan Brouer-Visser2,*,
  3. Laura Brennan2,
  4. Sabine Wilson1,
  5. Iakov I Davydov1,
  6. Nicolas Staedler1,
  7. José Duarte1,
  8. Iris Martinez Quetglas1,
  9. Eveline Nüesch3,
  10. Marta Cañamero4,
  11. Evelyne Chesné1,
  12. George Au-Yeung5,
  13. Erika Hamilton6,
  14. Stephanie Lheureux7,
  15. Debra L Richardson8,
  16. Iben Spanggaard9,
  17. Bruno Gomes10,
  18. Izolda Franjkovic4,
  19. Mark DeMario2,
  20. Martin Kornacker10,# and
  21. Katharina Lechner4,#
  1. 1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
  2. 2Roche Pharma Research and Early Development, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd, New York, NY, USA
  3. 3Product Development, Data Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
  4. 4Roche Pharma Research and Early Development, Roche Innovation Center Munich, F. Hoffmann-La Roche Ltd, Penzberg, Germany
  5. 5Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
  6. 6Sarah Cannon Research Institute, Nashville, TN, USA
  7. 7Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
  8. 8Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
  9. 9Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  10. 10Roche Pharma Research and Early Development, Oncology Early Clinical Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
  1. ↵†Corresponding author:
    Dr. Daniel Marbach, Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Email: daniel.marbach.dm1{at}roche.com

  1. ↵* Contributed equally to the work described in the manuscript

Back to top
Posted July 29, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)
Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, Sabine Wilson, Iakov I Davydov, Nicolas Staedler, José Duarte, Iris Martinez Quetglas, Eveline Nüesch, Marta Cañamero, Evelyne Chesné, George Au-Yeung, Erika Hamilton, Stephanie Lheureux, Debra L Richardson, Iben Spanggaard, Bruno Gomes, Izolda Franjkovic, Mark DeMario, Martin Kornacker, Katharina Lechner
medRxiv 2024.07.28.24309665; doi: https://doi.org/10.1101/2024.07.28.24309665
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area